Liminatus Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	-	0.06	0.43	5.05
Cash & Short-Term Investments	-	0.06	0.43	5.05
Cash Growth	-	-87.10%	-91.40%	-
Other Receivables	-	-	0.13	0.1
Receivables	-	3.67	0.95	0.1
Prepaid Expenses	-	0.16	0.02	0.01
Other Current Assets	-	1.4	0.84	1.68
Total Current Assets	-	5.28	2.24	6.84
Property, Plant & Equipment	-	0	0	0
Other Long-Term Assets	-	0.13	-	-
Total Assets	-	5.41	2.24	6.84
Accounts Payable	-	1.48	0.93	0.51
Accrued Expenses	0	3.1	0.86	0.44
Short-Term Debt	-	19.97	16.05	16.5
Other Current Liabilities	-	0.2	0.2	0.2
Total Current Liabilities	0	24.75	18.04	17.65
Total Liabilities	0	24.75	18.04	17.65
Common Stock	-	4.71	4.71	4.17
Additional Paid-In Capital	0	4.61	4.61	5.16
Retained Earnings	-0	-28.67	-25.12	-20.14
Shareholders' Equity	-0	-19.34	-15.79	-10.81
Total Liabilities & Equity	-	5.41	2.24	6.84
Total Debt	-	19.97	16.05	16.5
Net Cash (Debt)	-	-19.92	-15.62	-11.45
Net Cash Per Share	-	-0.18	-0.15	-0.32
Filing Date Shares Outstanding	26.01	112.22	112.22	35.56
Total Common Shares Outstanding	26.01	112.22	112.22	35.56
Working Capital	-0	-19.47	-15.8	-10.81
Book Value Per Share	-0.00	-0.17	-0.14	-0.30
Tangible Book Value	-0	-19.34	-15.79	-10.81
Tangible Book Value Per Share	-0.00	-0.17	-0.14	-0.30

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q